First patient dosed in Spaulding stroke recovery study of NIV-001

Neuro-Innovators said the first patient has been dosed in a clinical study at Spaulding Rehabilitation Hospital testing its combination therapy NIV-001 with intensive robot-assisted rehabilitation in people with chronic stroke disability. The trial is recruiting up to 50 participants and is designed to test whether the drug mix can improve motor recovery and function.

Why it matters: - Stroke is the leading cause of long-term disability worldwide. - The study is testing whether a drug therapy plus intensive rehabilitation can improve recovery in people who still live with chronic stroke-related disability. - A positive result could point to a new approach for improving function, independence and quality of life after stroke.

What happened: - Neuro-Innovators said the first patient was dosed in an investigator-initiated study at Mass General Brigham’s Spaulding Rehabilitation Hospital in Boston. - The trial evaluates NIV-001, Neuro-Innovators' proprietary combination of telmisartan, metformin and cilostazol. - Participants in the study are undergoing intensive robot-assisted upper-extremity rehabilitation. - The study is registered on ClinicalTrials.gov under identifier NCT07588932. - Spaulding Rehabilitation Hospital is recruiting up to 50 subjects.

The details: - The primary endpoint is the Fugl-Meyer Assessment, a validated measure of motor recovery. - The FDA accepted the Fugl-Meyer Assessment for the clearance of a stroke rehabilitation device. - NIV-001 is designed to support multiple biological pathways associated with recovery, including neurogenesis, angiogenesis and bioenergetics. - The therapeutic approach also aims to modulate inflammation. - Neuro-Innovators says the goal is to enhance neuroplasticity, or the brain's ability to adapt, repair and recover function. - The company said the first patient dose is an important milestone in the clinical advancement of NIV-001. - Neuro-Innovators also said the milestone follows a recently filed patent application tied to its multi-mechanism approach to promoting recovery after neurological injury.

Between the lines: - The study is not testing rehabilitation alone. It is testing whether a biologically targeted therapy can amplify the effects of intensive therapy. - The design reflects a broader idea in neurorestorative medicine: recovery may require multiple pathways to be supported at the same time. - Company executives and Spaulding researchers framed the trial as an early test of whether that combined approach can move stroke care beyond functional compensation toward functional restoration.

What's next: - Spaulding Rehabilitation Hospital will continue enrolling patients for the study. - Researchers will measure whether NIV-001 plus rehabilitation improves outcomes on the Fugl-Meyer Assessment. - Neuro-Innovators said it expects the study to generate insights that may advance neurorestorative medicine. - The company says it will continue developing compound therapies for recovery after stroke, brain injury and other neurological conditions.

The bottom line: - Neuro-Innovators has moved its lead combination therapy into human testing, and the outcome will help show whether pairing medication with intensive rehabilitation can improve chronic stroke recovery.